Novo Nordisk jump after positive investor reaction at medical conference in Vienna

** U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO, NVO.N rise 7.8% to $62.72 premarket

** Investors turned more positive about Novo's prospects following a key diabetes conference held in Vienna this week

** Company said on September 10 it will cut 9,000 jobs in a bid to reduce costs and fend off intense competition from U.S. rival Eli Lilly LLY.N

** In July, company also named Maziar Mike Doustdar as its new CEO effective August 7

** Novo did not unveil groundbreaking data at the European Association for the Study of Diabetes conference, but the company was "changing commercial focus" under Doustdar, Barclays said in a research note

** As of last close, stock down 32.3% YTD